(Reuters) – The British government has ordered 40 million further doses of Valneva’s COVID-19 vaccine candidate for 2022, the French drugmaker said on Monday.
This brings Britain’s total orders to 100 million doses, while it retains options for a further 90 million doses between 2023 and 2025, the company said in a statement.
The firm expects a read-out of its Phase I/II clinical trial within three months.
(Reporting by Sarah Morland in Gdansk; Editing by Himani Sarkar)
